Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.

This paper describes a three-dimensional quantitative structure-selectivity relationships (3D-QSSR) study for selectivity of a series of ligands for cannabinoid CB1 and CB2 receptors. 3D-QSSR exploration was expected to provide design information for drugs with high selectivity toward the CB2 receptor. The proposed 3D computational model was performed by Phase and generated taking into account a number of structurally diverse compounds characterized by a wide range of selectivity index values. The model proved to be predictive, with r2 of 0.95 and Q2 of 0.63. In order to get prospective experimental validation, the selectivity of an external data set of 39 compounds reported in the literature was predicted. The correlation coefficient (r2=0.56) obtained on this unrelated test set provided evidence that the correlation shown by the model was not a chance result. Subsequently, we essayed the ability of our approach to help the design of new CB2-selective ligands. Accordingly, based on our interest in studying the cannabinergic properties of quinolones, the N-(adamantan-1-yl)-4-oxo-8-methyl-1-pentyl-1,4-dihydroquinoline-3-carboxamide (65) was considered as a potential synthetic target. The log(SI) value predicted by using our model was indicative of high CB2 selectivity for such a compound, thus spurring us to synthesize it and to evaluate its CB1 and CB2 receptor affinity. Compound 65 was found to be an extremely selective CB2 ligand as it displayed high CB2 affinity (Ki=4.9 nM), while being devoid of CB1 affinity (Ki>10,000 nM). The identification of a new selective CB2 receptor ligand lends support for the practicability of quantitative ligand-based selectivity models for cannabinoid receptors. These drug discovery tools might represent a valuable complementary approach to docking studies performed on homology models of the receptors.

[1]  S. Nikas,et al.  Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols , 2002 .

[2]  Serdar Durdagi,et al.  The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. , 2007, Journal of medicinal chemistry.

[3]  Michael Koblish,et al.  Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability. , 2010, Bioorganic & medicinal chemistry letters.

[4]  S. Durdağı,et al.  A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis , 2010, Molecular Diversity.

[5]  R. Pertwee,et al.  Therapeutic Applications for Agents that Act at CB1 and CB2 Receptors , 2009 .

[6]  P. Lazzari,et al.  Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. , 2006, Journal of medicinal chemistry.

[7]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[8]  E. Novellino,et al.  Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. , 2008, Journal of medicinal chemistry.

[9]  P. Chandran,et al.  Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. , 2010, Journal of medicinal chemistry.

[10]  G. Hynd,et al.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. , 2005, Bioorganic & medicinal chemistry.

[11]  R. Dolle,et al.  Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands. , 2009, Current pharmaceutical design.

[12]  G. Fox,et al.  Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging , 2009, Journal of Pharmacology and Experimental Therapeutics.

[13]  Qian Liu,et al.  3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. , 2006, Journal of medicinal chemistry.

[14]  Michael Koblish,et al.  CB2 selective sulfamoyl benzamides: optimization of the amide functionality. , 2009, Bioorganic & medicinal chemistry letters.

[15]  G. Gessa,et al.  Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. , 2004, Bioorganic & medicinal chemistry.

[16]  Michael Koblish,et al.  Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists. , 2009, Bioorganic & medicinal chemistry letters.

[17]  G. Cruciani,et al.  A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. , 2000, Journal of Medicinal Chemistry.

[18]  A. Makriyannis,et al.  Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol. , 1999, Bioorganic & medicinal chemistry letters.

[19]  R. Pertwee,et al.  Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630 , 1999, British journal of pharmacology.

[20]  G. Velasco,et al.  Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.

[21]  I. Chessell,et al.  Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. , 2007 .

[22]  S. Yu,et al.  3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. , 1999, Bioorganic & medicinal chemistry.

[23]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[24]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[25]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[26]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Thierry Langer,et al.  Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. , 2009, Journal of medicinal chemistry.

[29]  Y. Toda,et al.  N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability. , 2007, Bioorganic & medicinal chemistry letters.

[30]  Alexandros Makriyannis,et al.  Structural biology of human cannabinoid receptor-2 helix 6 in membrane-mimetic environments. , 2009, Biochemical and biophysical research communications.

[31]  Gerhard Klebe,et al.  3D QSAR Selectivity Analyses of Carbonic Anhydrase Inhibitors: Insights for the Design of Isozyme Selective Inhibitors , 2006, J. Chem. Inf. Model..

[32]  M. Krishnamurthy,et al.  Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. , 2008, Bioorganic & medicinal chemistry.

[33]  R. Razdan,et al.  Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[34]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[35]  F. Mauler,et al.  3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects , 2004, Journal of Pharmacology and Experimental Therapeutics.

[36]  L. Koetzner,et al.  Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy , 2005, Neuropharmacology.

[37]  R. Pertwee,et al.  O‐1057, a potent water‐soluble cannabinoid receptor agonist with antinociceptive properties , 2000, British journal of pharmacology.

[38]  Philippe Chavatte,et al.  Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. , 2006, Journal of medicinal chemistry.

[39]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[40]  J. Lange,et al.  Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. , 2010, Bioorganic & medicinal chemistry letters.

[41]  R. Pertwee,et al.  Pharmacology of cannabinoid receptor ligands. , 1999, Current medicinal chemistry.

[42]  Y. Toda,et al.  Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists. , 2007, Bioorganic & medicinal chemistry letters.

[43]  M. Cascio,et al.  In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. , 2010, Pharmacological research.

[44]  M. Cascio,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands. , 2010, Journal of medicinal chemistry.

[45]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[47]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[48]  L. Botta,et al.  Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. , 2008, Journal of medicinal chemistry.

[49]  Wei Li,et al.  Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. , 2003, Bioorganic & medicinal chemistry.

[50]  A. Howlett The cannabinoid receptors. , 2002, Prostaglandins & other lipid mediators.

[51]  A. Malikzay,et al.  Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[52]  A. Makriyannis,et al.  Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? , 2009, Trends in pharmacological sciences.

[53]  D. Bashford,et al.  Quantitative structure-activity relationship (QSAR) for a series of novel cannabinoid derivatives using descriptors derived from semi-empirical quantum-chemical calculations. , 2009, Bioorganic & medicinal chemistry.

[54]  V. Marzo,et al.  Targeting the endocannabinoid system: to enhance or reduce? , 2008, Nature Reviews Drug Discovery.

[55]  Y. Toda,et al.  Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. , 2008, Bioorganic & medicinal chemistry.

[56]  Andrew J. Brown,et al.  Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain. , 2010, Bioorganic & medicinal chemistry letters.

[57]  P. Fossa,et al.  CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists , 2010, Journal of molecular modeling.

[58]  N. Romeiro,et al.  Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. , 2009, European journal of medicinal chemistry.